Two companies collaborating on breast cancer vaccine.

2003 NOV 17 - (NewsRx.com & NewsRx.net) -- Bavarian Nordic and Pharmexa have entered into a collaborative agreement that will test the use of Bavarian Nordic's proprietary MVA-BN vector technology in combination with Pharmexa's HER-2 DNA AutoVac vaccine.

The parties expect that Phase l/ll clinical trials could begin in Germany and Italy within 18 months.

In 2002, Pharmexa announced promising results with its HER-2 DNA AutoVac vaccine in a Phase l/ll clinical trial with 27 breast cancer patients. Trial results showed that the vaccine was safe and could induce a cytotoxic T-lymphocyte (CTL) -based immune response in breast cancer patients.

In the new …